RxDoctor Payments Data

Asia Sullivan

Physician Assistant · Los Angeles, CANPI 1073074332

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by GSK at 39.3% of the total. 2025 is the largest year on record at $24,474, 4.1 times the $6,023 reported in 2021. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,907in general payments, 2019–2025

Across 882 payments — averaging $69.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$24K
  • Viiv Healthcare Company$17K
  • Gilead$8K
  • Eko Health, Inc.$2K
  • EMD Serono, Inc.$1K
  • Biohaven Pharmaceuticals, Inc.$873
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$27,00844%
  • Speaking & faculty fees$6,10010%
  • Travel & lodging$5,1919%
  • Food & beverage$21,36935%
  • Education$1300%
  • Other$1,1092%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,907 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin12$184,108
Egrifta SvTesamorelin Acetate18$131,011
BiktarvyBictegrav/Emtricit/Tenofov Ala29$123,696
DovatoDolutegravir Sodium/Lamivudine27$78,977
PrezcobixDarunavir/Cobicistat21$73,433
TivicayDolutegravir Sodium21$66,967
DescovyEmtricitabine/Tenofov Alafenam19$61,638
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$42,779
MounjaroTirzepatide20$19,613
XyostedTestosterone Enanthate13$7,978
MovantikNaloxegol Oxalate14$7,279
VascepaIcosapent Ethyl15$6,031
Testosterone43$5,722
Testosterone Cypionate31$1,746
Ondansetron Hcl15$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$8,463$185,33448 claims
EMD Serono, Inc.Serostim$1,150$184,10812 claims
Viiv Healthcare CompanyDovato, Tivicay$16,836$145,94448 claims
Theratechnologies Inc.Egrifta Sv$412$131,01118 claims
Johnson & JohnsonPrezcobix$742$73,43321 claims
Lilly USA, LLCMounjaro$312$19,61320 claims
Antares Pharma, Inc.Xyosted$230$7,97813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →